Phase 1CompletedAge-related condition
Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer
- Sponsor
- Panacela Labs LLC (Industry)
- Enrollment
- 32 enrolled
- Conditions
- Prostate Cancer
- Interventions
- Mobilan (M-VM3); Placebo
- Ages
- adults, older adults
- Registry
- NCT02654938
Full record on ClinicalTrials.gov
From the registry
Phase I single-blinded, randomized, placebo-controlled trial evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of single injections of ascending doses of investigational drug product Mobilan (М-VM3) administered directly into the prostate of patients with prostate cancer.
Primary outcomes
- Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)
History
Last registry update
Primary completion
Registered
Started